Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
Plans under the federal health insurance program are still prohibited from covering Wegovy, Mounjaro and other GLP-1s for weight loss
Cardiac Toxicity From Chemoradiation With Or Without Surgery for Patients With Esophageal Cancers
Book your vitamin injection appointment today and experience the Vital Flow difference
Add two short strength sessions per week built around push, pull, hinge, squat, and carry
Many people who've been on a GLP-1 stop after about one year, according to a 2024 study in JAMA Network Open